Disclaimer from the CiPA Steering Team

The Comprehensive in Vitro Proarrhythmia Assay (CiPA) Steering Team is comprised of partners from the US FDA, HESI, CSRC, SPS, Japan NIHS, PMDA, EMA and Health Canada. There are four CiPA Work Streams including: In Silico, Myocyte, Ion Channel, and Clinical ECG, and additional organizations and individual scientists are contributing to the CiPA efforts via the work streams. Participation in any of the CiPA groups or studies does not constitute endorsement from the CiPA Steering Team or other participating members of the consortia. There is no certification process for CiPA or any CiPA protocols.

The CiPA Steering Team and Work Streams operate in a precompetitive space where studies are collectively designed with the best possible science in mind and without bias toward any vendors, cell providers, contract research organizations (CROs) or instrument manufacturers. The goal of these studies is not to select any one platform or cell provider, but rather to determine minimum endpoints, reproducibility, and validity of all assays for the purpose of CiPA.

All completed studies are published in the peer reviewed literature and posted to the CiPA website (https://cipaproject.org/publications/). Data is made available to the extent possible on the website (https://cipaproject.org/data-resources/). Any official protocols or updates will be posted to the CiPA website.

A CiPA logo has been created for the project. Use of the CiPA logo is encouraged for all partners. However, use of the CiPA name or logo does not constitute endorsement from the CiPA Steering Team or other participating members of the consortia.